Noveltreat
by Sun Pharma · DCGI approved December 2025
| Active ingredient | Semaglutide (GLP-1 receptor agonist) |
| Indication | Obesity (Chronic Weight Management) |
| Manufacturer | Sun Pharmaceutical Industries Ltd |
| DCGI status | Approved December 2025 |
| Price (MRP) | ₹750–2,000/month |
| Format | Prefilled pen Concealed needle, single-strength prefilled pen |
| Prescription | Schedule H — required |
How Noveltreat compares
Noveltreat is Sun Pharma's obesity-indicated brand of generic semaglutide, approved by DCGI in December 2025 — the first Indian generic at the obesity dose. The concealed-needle prefilled pen reduces injection-related anxiety, a key adoption barrier for first-time semaglutide users.
About Sun Pharma
Sun Pharma is India's largest pharmaceutical company by revenue. Its semaglutide programme includes a Phase III clinical trial conducted in India, supporting an Indian-population safety and efficacy profile. Sun Pharma also markets Sematrinity, the type-2-diabetes indication of the same molecule.
Manufacturer announcement
Additional source
Sun Pharma DCGI approval PRGLP-1 Check is informational, not a medical diagnosis. Semaglutide is a Schedule H drug in India and requires a prescription from a registered medical practitioner. Always consult a qualified physician before starting any treatment.